SI
AZN icon

Sofinnova Investments’s AstraZeneca AZN Stock Holding History

Sofinnova Investments’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.9M Sell
456,031
-360,136
-44% -$69.4M 3.42% 8
2025
Q4 		$150M Buy
816,167
+404,200
+98% +$70.9M 6.47% 3
2025
Q3 		$63.2M Buy
411,967
+265,136
+181% +$40.1M 3.46% 6
2025
Q2 		$20.5M Buy
+146,831
New +$20.6M 1.26% 26
2025
Q1 		– Sell
-325,672
Closed -$42.7M – 70
2024
Q4 		$42.7M Sell
325,672
-79,031
-20% -$11.1M 3.11% 8
2024
Q3 		$63.1M Buy
404,703
+3,994
+1% +$645K 5% 4
2024
Q2 		$62.5M Buy
400,709
+102,352
+34% +$15.4M 3.25% 8
2024
Q1 		$40.4M Sell
298,357
-126,932
-30% -$16.8M 2.25% 15
2023
Q4 		$57.3M Sell
425,289
-256,129
-38% -$33.3M 3.2% 7
2023
Q3 		$92.3M Sell
681,418
-167,341
-20% -$22.9M 5.82% 3
2023
Q2 		$121M Buy
+848,759
New +$125M 7.96% 3
2023
Q1 		– Sell
-306,837
Closed -$41.6M – 56
2022
Q4 		$41.6M Sell
306,837
-44,102
-13% -$5.53M 2.47% 11
2022
Q3 		$38.5M Buy
350,939
+192,759
+122% +$24.5M 2.24% 10
2022
Q2 		$20.9M Sell
158,180
-118,772
-43% -$15.6M 1.74% 16
2022
Q1 		$36.7M Buy
+276,952
New +$33.2M 2.79% 8
2021
Q4 		– Sell
-564,136
Closed -$67.8M – 73
2021
Q3 		$67.8M Buy
564,136
+84,320
+18% +$9.82M 4.01% 5
2021
Q2 		$57.5M Sell
479,816
-38,050
-7% -$4.17M 3.31% 6
2021
Q1 		$51.5M Buy
517,866
+96,566
+23% +$9.71M 3.1% 6
2020
Q4 		$42.1M Buy
+421,300
New +$44.6M 2.51% 7
2019
Q2 		– Sell
-130,789
Closed -$10.6M – 72
2019
Q1 		$10.6M Sell
130,789
-27,375
-17% -$2.16M 1.02% 20
2018
Q4 		$12M Buy
158,164
+37,860
+31% +$2.96M 1.5% 17
2018
Q3 		$9.52M Sell
120,304
-44,596
-27% -$3.37M 0.85% 22
2018
Q2 		$11.6M Buy
164,900
+153,984
+1,411% +$11.1M 1.31% 19
2018
Q1 		$763K Buy
+10,916
New +$756K 0.13% 23

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Sofinnova Investments's AZN Position: Q1 2026 in Review

Sofinnova Investments reduced its AstraZeneca (AZN) stake by 44% in Q1 2026, selling an estimated $69.4M and leaving 456,031 shares worth $89.9M. The position accounts for 3.42% of the portfolio, ranked #8.

Sofinnova Investments first reported a position in AZN in Q1 2018 and has held it in 24 quarters since. The position peaked at $150M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Sofinnova Investments held 456,031 shares of AstraZeneca worth $89.9M as of Q1 2026.
  • Sofinnova Investments sold 360,136 AstraZeneca shares in Q1 2026, an estimated $69.4M.
  • AstraZeneca made up 3.42% of Sofinnova Investments's portfolio in Q1 2026, its #8 holding.
  • Sofinnova Investments first reported a position in AstraZeneca in Q1 2018 and has held it in 24 quarters since.
  • Sofinnova Investments's AstraZeneca position peaked at $150M in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.